CN106722160A - A kind of bitter buckwheat bud chewable tablets with healthcare function and preparation method thereof - Google Patents
A kind of bitter buckwheat bud chewable tablets with healthcare function and preparation method thereof Download PDFInfo
- Publication number
- CN106722160A CN106722160A CN201611054875.5A CN201611054875A CN106722160A CN 106722160 A CN106722160 A CN 106722160A CN 201611054875 A CN201611054875 A CN 201611054875A CN 106722160 A CN106722160 A CN 106722160A
- Authority
- CN
- China
- Prior art keywords
- bitter buckwheat
- buckwheat bud
- chewable tablets
- bud
- healthcare function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000219051 Fagopyrum Species 0.000 title claims abstract description 114
- 235000009419 Fagopyrum esculentum Nutrition 0.000 title claims abstract description 114
- 239000007910 chewable tablet Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 34
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 20
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 20
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 20
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940041616 menthol Drugs 0.000 claims abstract description 20
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 20
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 20
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 20
- 229940013618 stevioside Drugs 0.000 claims abstract description 20
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000019202 steviosides Nutrition 0.000 claims abstract description 20
- 239000000811 xylitol Substances 0.000 claims abstract description 20
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 20
- 235000010447 xylitol Nutrition 0.000 claims abstract description 20
- 229960002675 xylitol Drugs 0.000 claims abstract description 20
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 18
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 18
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000011122 softwood Substances 0.000 claims description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- 239000003826 tablet Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 10
- 239000011812 mixed powder Substances 0.000 claims description 10
- 238000007605 air drying Methods 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 5
- 230000001070 adhesive effect Effects 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 238000005286 illumination Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 230000000474 nursing effect Effects 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 210000002966 serum Anatomy 0.000 abstract description 9
- 210000005013 brain tissue Anatomy 0.000 abstract description 8
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract description 4
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract description 4
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract description 4
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 4
- 235000019605 sweet taste sensations Nutrition 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000000717 retained effect Effects 0.000 abstract description 2
- 230000006870 function Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000007654 immersion Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- -1 flavone compounds Chemical class 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229940057948 magnesium stearate Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000013441 quality evaluation Methods 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000010030 glucose lowering effect Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000697 sensory organ Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 244000130270 Fagopyrum tataricum Species 0.000 description 1
- 235000014693 Fagopyrum tataricum Nutrition 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003026 anti-oxygenic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a kind of bitter buckwheat bud chewable tablets with healthcare function and preparation method thereof, and the bitter buckwheat bud chewable tablets is made up of the raw material of following weight/mass percentage composition：Bitter buckwheat bud powder 20 40%, microcrystalline cellulose 15 25%, xylitol 14.4 30%, stevioside 0.15 0.3%, menthol 0.075 0.15%, maltodextrin adds to 100%, bitter buckwheat bud is eliminated herbaceous taste by the present invention through low fiery frying, make its chewiness good, instant, uniform color, sweet taste and mint flavored are moderate, the present invention is by bitter buckwheat bud and maltodextrin, microcrystalline cellulose, xylitol, stevioside, the component compatibilities such as menthol, outside the original effect of bitter buckwheat bud is retained, also produce synergy, make bitter buckwheat bud chewable tablets that there is antioxidation, the content of MDA in serum can be significantly reduced, improve GSH PX activity and T SOD activity in brain tissue, with edible medical value higher and economic benefit.
Description
Technical field
The invention belongs to food research technical field, more particularly to a kind of bitter buckwheat bud chewable tablets with healthcare function and its
Preparation method.
Background technology
Bitter buckwheat contains a large amount of flavone compounds, can maintain the permeability of capillary and reduce its fragility, promotes cell
Hyperplasia and the aggegation for preventing haemocyte, the also work of the aspect such as anti-inflammatory, antiallergy, diuresis, spasmolysis, antibechic, reducing blood lipid, cardiac stimulant
With.The Quercetin of bitter buckwheat has good eliminating the phlegm, cough-relieving and certain antiasthmatic effect；Still can hypotensive, blood fat, expand coronal dynamic
Arteries and veins, plays the role of to increase coronary blood flow.Bitter buckwheat also containing the inorganic elements of multiple beneficial human body, can not only improve people
The content of internal indispensable element, may also operate as protection hepatic and renal function, hematopoiesis function and enhancing immunologic function, reaches salubrity and is good for
Brain, intelligence development, keep cardiovascular normal, reduce the effect of cholesterol.Modern medicine study shows that bitter buckwheat food has obvious drop
Blood fat, hypoglycemic, urine glucose lowering effect, it has special efficacy to diabetes, to high fat of blood, cerebrovascular sclerosis, cardiovascular disease, hypertension etc.
Disease has good preventive and therapeutic action.Bitter buckwheat also has radiation protection characteristic higher.
Although bitter buckwheat contains multiple beneficial composition, simultaneously containing various ANFs such as protease inhibitors, make egg
The absorption rate reduction of the nutritional ingredients such as white matter, and bitter buckwheat is eaten in forms such as tartary buckwheat tea, buckwheat powders as product more at present
With the report for bitter buckwheat bud is relatively fewer, and many based on eating raw, and fresh bitter buckwheat bud has herbaceous taste, slight bitter, mouthfeel
Difference, does not meet popular taste.
The content of the invention
Good the invention provides a kind of delicious, chewiness, uniform color and with antioxidation can significantly reduce blood
The content of clear middle MDA simultaneously improves brain tissue GSH-PX activity and the active bitter buckwheat bud chewable tablets with healthcare function of T-SOD.
Meanwhile, present invention also offers the preparation method of the above-mentioned bitter buckwheat bud chewable tablets with healthcare function, its low cost,
With short production cycle, nutrition leak is few.
To achieve the above object, the technical solution adopted in the present invention is as follows：
The bitter buckwheat bud chewable tablets is made up of the raw material of following weight/mass percentage composition：
Further, the bitter buckwheat bud chewable tablets is preferably made up of the raw material of following weight/mass percentage composition：
Further, the bitter buckwheat bud chewable tablets is made up of the raw material of following weight/mass percentage composition：Bitter buckwheat bud powder 25%, malt
Dextrin 25.025%, microcrystalline cellulose 25%, xylitol 24.6%, stevioside 0.25%, menthol 0.125%.
Further, magnesium stearate is also included in above-mentioned raw materials, the content of magnesium stearate is the 0.6- of other raw material gross masses
1.0%.
A kind of preparation method of the above-mentioned bitter buckwheat bud chewable tablets with healthcare function, it is comprised the following steps：
(1) drying bitter buckwheat bud is crushed, crosses 100 mesh sieves and bitter buckwheat bud powder is obtained, 400-600W is low fiery frying 6-10 minutes, standby
With；
(2) maltodextrin, microcrystalline cellulose, xylitol, stevioside and menthol are taken to crush, 100 mesh sieves is crossed respectively, will
The bitter buckwheat bud powder of crushing, maltodextrin, microcrystalline cellulose, xylitol, stevioside, menthol are mixed and stirred for according to formula ratio
It is even, obtain mixed powder；
(3) mixed powder in step (2) is slowly added to 50%-70% ethanol solutions as adhesive, adjustment material
Humidity, is made softwood, and softwood should be held agglomerating, touch and dissipate, and softwood is crossed into 20 mesh sieves wet grain is obtained；
(4) wet grain is placed in into the drying box that temperature is 50-100 DEG C to be dried, is dried to its water content below 5%,
Obtain dry particle；
(5) dry particle is weighed, sprays appropriate 50%-75% alcohol, stirred, compressing tablet is obtained with health care
The bitter buckwheat bud chewable tablets of function.
Drying bitter buckwheat bud in above-mentioned steps (1) is obtained by following methods：Screen the bitter buckwheat wash seeds of full grains
Totally, 12-24h is soaked for the 2-3 times of clear water of buckwheat seed volume, soaked seed is uniformly sowed seeds in tiling wet yarn
In the seedlings nursing plate of cloth, be placed in 20-25 DEG C of temperature, humidity be 75%-80% dark surrounds in vernalization 24-48h, after identical
Temperature, humidity and daily illumination 8-12h under conditions of cultivate, timing is sprayed water, and is harvested after 10-12d；Fresh bitter buckwheat bud is uniform
Spread out, 60 DEG C of -100 DEG C of heated-air dryings to water content be less than 5%, be filled to hermetic bag freezing keep in dark place it is standby.
Further, above-mentioned steps (5) are that dry particle is weighed, and add dolomol, are well mixed, and sprinkling is appropriate
50%-75% alcohol, stirs, compressing tablet, that is, obtain the bitter buckwheat bud chewable tablets with healthcare function.
Bitter buckwheat bud chewable tablets with healthcare function provided by the present invention, takes full advantage of the nutritive value of bitter buckwheat bud,
Flavonoid substances content increase particularly rutin content particularly enriches in bitter buckwheat bud after sprouting, substantially reduces or eliminate bitter buckwheat
The content of middle ANFs, and bitter buckwheat bud is eliminated into herbaceous taste through low fiery frying, make its chewiness good, instant, color
Damp uniform, sweet taste and mint flavored are moderate, in routine with reducing blood lipid, hypoglycemic, urine glucose lowering effect, to high fat of blood, the cerebrovascular
While the diseases such as hardening, cardiovascular disease, hypertension have good preventive and therapeutic action, the present invention pastes bitter buckwheat bud and malt
The component compatibilities such as essence, microcrystalline cellulose, xylitol, stevioside, menthol, outside the original effect of bitter buckwheat bud is retained, also produce
Raw synergy, makes obtained bitter buckwheat bud chewable tablets have antioxidation, can significantly reduce the content of MDA in serum, carries
GSH-PX activity and T-SOD activity in brain tissue high, with edible medical value higher and economic benefit, additionally, of the invention
Preparation method is with short production cycle, low cost, nutrition leak is few, is suitable to industrialized production.
Specific embodiment
According to following embodiments, the present invention may be better understood.But as it will be easily appreciated by one skilled in the art that implement
Concrete technology condition, material percentage composition and its result described by example are merely to illustrate the present invention, without that will not also should limit
The present invention described in claims processed.
Embodiment 1
The bitter buckwheat bud chewable tablets of the present embodiment, material quality percentage composition constitutes and is：Bitter buckwheat bud powder 25%；Maltodextrin
25.025%；Microcrystalline cellulose 25%；Xylitol 24.6%；Stevioside 0.25%；Menthol 0.125%, magnesium stearate is it
The 1.0% of his raw material gross mass.
Its preparation method, comprises the following steps：
(1) the bitter buckwheat wash seeds of screening full grains are clean, 3 times of clear water immersion 12h of buckwheat seed volume, immersion
Good seed is uniform to sow seeds in the seedlings nursing plate that tiling has wet gauze, is placed in 25 DEG C of temperature, during humidity is 80% dark surrounds
Vernalization 48h, is cultivated under conditions of identical temperature, humidity and daily illumination 12h, and timing is sprayed water, and is harvested after 10d, will be new
Fresh bitter buckwheat bud is uniformly spread out, 100 DEG C of heated-air dryings to water content be less than 5%, be filled to hermetic bag freezing keep in dark place it is standby；
(2) drying bitter buckwheat bud is crushed, crosses 100 mesh sieves and bitter buckwheat bud powder is obtained, the low fiery fryings of 500W 6 minutes are standby；
(3) maltodextrin, microcrystalline cellulose, xylitol, stevioside, menthol, magnesium stearate are taken to crush, 100 is crossed respectively
Mesh sieve is standby；
(4) the bitter buckwheat bud powder after above-mentioned crushing, maltodextrin, microcrystalline cellulose, xylitol, stevioside, menthol are pressed
It is mixed and stirred for uniformly, obtaining mixed powder according to formula ratio；
(5) mixed powder in step (4) is slowly added to 75% ethanol solution as adhesive, humidity of materials is adjusted,
It is made softwood, softwood should be held agglomerating, touch and dissipate, and softwood is crossed into 20 mesh sieves wet grain is obtained.
(6) wet grain is placed in into the drying box that temperature is 100 DEG C to be dried, is dried to its water content below 5%, obtained
Dry particle.
(7) dry particle is weighed, and adds magnesium stearate as lubricant, is well mixed, and sprays appropriate 75% alcohol, stirring
Uniformly, compressing tablet in tablet press machine is placed in, the bitter buckwheat bud chewable tablets with healthcare function is obtained.
Chewable tablets color and luster distribution uniform obtained by the formula rate, profile are complete, chewiness is good, sweet taste and mint flavored
It is moderate；Hardness is suitable, is 4.78 ± 0.78, and tablet weight variation is less than ± 5%, and friability is 0.255%, meets the correlation of pharmacopeia
Regulation.
Embodiment 2
The bitter buckwheat bud chewable tablets of the present embodiment, material quality percentage composition composition is as follows：Bitter buckwheat bud powder 30%；Maltodextrin
20%；Microcrystalline cellulose 20%；Xylitol 29.55%；Stevioside 0.3%；Menthol 0.15%；Magnesium stearate is other raw materials
The 0.8% of gross mass.
Its preparation method, comprises the following steps：
(1) the bitter buckwheat wash seeds of screening full grains are clean, 2 times of clear water immersion 24h of buckwheat seed volume, immersion
Good seed is uniform to sow seeds in the seedlings nursing plate that tiling has wet gauze, is placed in 20 DEG C of temperature, during humidity is 75% dark surrounds
Vernalization 36h, is cultivated under conditions of identical temperature, humidity and daily illumination 10h, and timing is sprayed water, and is harvested after 12d, will be new
Fresh bitter buckwheat bud is uniformly spread out, 80 DEG C of heated-air dryings to water content be less than 5%, be filled to hermetic bag freezing keep in dark place it is standby；
(2) drying bitter buckwheat bud is crushed, crosses 100 mesh sieves and bitter buckwheat bud powder is obtained, the low fiery fryings of 600W 6 minutes are standby；
(3) maltodextrin, microcrystalline cellulose, xylitol, stevioside, menthol, magnesium stearate are taken to crush, 100 is crossed respectively
Mesh sieve is standby；
(4) the bitter buckwheat bud powder after above-mentioned crushing, maltodextrin, microcrystalline cellulose, xylitol, stevioside, menthol are pressed
It is mixed and stirred for uniformly, obtaining mixed powder according to formula ratio；
(5) mixed powder in step (4) is slowly added to 50% ethanol solution as adhesive, humidity of materials is adjusted,
It is made softwood, softwood should be held agglomerating, touch and dissipate, and softwood is crossed into 20 mesh sieves wet grain is obtained.
(6) wet grain is placed in into the drying box that temperature is 80 DEG C to be dried, is dried to its water content below 5%, obtained
Dry particle.
(7) dry particle is weighed, and adds magnesium stearate as lubricant, is well mixed, and sprays appropriate 50% alcohol, stirring
Uniformly, compressing tablet in tablet press machine is placed in, the bitter buckwheat bud chewable tablets with healthcare function is obtained.
Embodiment 3
The bitter buckwheat bud chewable tablets of the present embodiment, material quality percentage composition composition is as follows：
Bitter buckwheat bud powder 20%；Maltodextrin 44.69%；Microcrystalline cellulose 15%；Xylitol 20%；Stevioside 0.21%；
Menthol 0.1%；Magnesium stearate is the 0.6% of other raw material gross masses.
Its preparation method, comprises the following steps：
(1) the bitter buckwheat wash seeds of screening full grains are clean, 3 times of clear water immersion 12h of buckwheat seed volume, immersion
Good seed is uniform to sow seeds in the seedlings nursing plate that tiling has wet gauze, is placed in 23 DEG C of temperature, during humidity is 80% dark surrounds
Vernalization 24h, is cultivated under conditions of identical temperature, humidity and daily illumination 8h, and timing is sprayed water, and is harvested after 10d, will be fresh
Bitter buckwheat bud is uniformly spread out, 60 DEG C of heated-air dryings to water content be less than 5%, be filled to hermetic bag freezing keep in dark place it is standby；
(2) drying bitter buckwheat bud is crushed, crosses 100 mesh sieves and bitter buckwheat bud powder is obtained, the low fiery fryings of 600W 6 minutes are standby；
(3) maltodextrin, microcrystalline cellulose, xylitol, stevioside, menthol, magnesium stearate are taken to crush, 100 is crossed respectively
Mesh sieve is standby；
(4) the bitter buckwheat bud powder after above-mentioned crushing, maltodextrin, microcrystalline cellulose, xylitol, stevioside, menthol are pressed
It is mixed and stirred for uniformly, obtaining mixed powder according to formula ratio；
(5) mixed powder in step (4) is slowly added to 50% ethanol solution as adhesive, humidity of materials is adjusted,
It is made softwood, softwood should be held agglomerating, touch and dissipate, and softwood is crossed into 20 mesh sieves wet grain is obtained.
(6) wet grain is placed in into the drying box that temperature is 80 DEG C to be dried, is dried to its water content below 5%, obtained
Dry particle.
(7) dry particle is weighed, and adds magnesium stearate as lubricant, is well mixed, and sprays appropriate 50% alcohol, stirring
Uniformly, compressing tablet in tablet press machine is placed in, the bitter buckwheat bud chewable tablets with healthcare function is obtained.
Embodiment 4
The bitter buckwheat bud chewable tablets of the present embodiment, material quality percentage composition composition is as follows：
Bitter buckwheat bud powder 40%；Maltodextrin 20.375%；Microcrystalline cellulose 25%；Xylitol 14.4%；Stevioside
0.15%；Menthol 0.075%.
Its preparation method is same as the previously described embodiments.
In order to further verify beneficial effects of the present invention, applicant done it is substantial amounts of verified, it is specific as follows：
(1) mouthfeel of bitter buckwheat bud chewable tablets and quality evaluation
Bitter buckwheat bud powder 25%；Maltodextrin 25.025%；Microcrystalline cellulose 25%；Xylitol 24.6%；Stevioside
0.25%；Menthol 0.125%；Magnesium stearate accounts for the 1.0% of other raw material gross masses.Three lot samples are obtained using above-mentioned formula
Product, sense organ and quality evaluation result as shown in table 1, the three batches of formula rate chewable tablets color and luster distribution uniforms, outer as seen from the table
Shape is complete, chewiness is good, sweet taste and mint flavored are moderate；And hardness is suitable, tablet weight variation and friability meet the correlation of pharmacopeia
Regulation.
1 three batches of bitter buckwheat bud chewable tablets sense organs of table and quality evaluation
(2) antioxygenic property of bitter buckwheat bud
2.1 medicines and reagent：
Bitter buckwheat bud chewable tablets powder：A black rich bitter buckwheat seed is harvested after planting 10 days, is crushed after 60 DEG C of heated-air dryings
Sieve series obtains bitter buckwheat bud, and the method according still further to embodiment 1 is obtained bitter buckwheat bud chewable tablets powder；Vitamin E：Sigma companies；D- galas
Sugar：Amresco companies of the U.S.；GSH-PX, T-SOD, MDA determine kit：Bioengineering Research Institute is built up in Nanjing.
2.2 animals：
Cleaning grade Kunming mouse：Male is, 20 ± 2g of body weight, Xi'an Communications University's Experimental Animal Center is provided.
2.3 animal packets and treatment：
Mouse normally raise be randomly divided into after 5d blank control group, positive controls, model control group and bitter buckwheat bud it is low,
Middle and high dosage group, every group each 10.Basic, normal, high dosage group difference gavage bitter buckwheat bud chewable tablets powder suspension 1g/kgd, 2g/
Kgd, 4g/kgd, blank control group and model control group give same volume physiological saline, and positive controls give vitamin E
(60mg/kg·d).In addition to blank control group, the daily intraperitoneal injection D- galactolipins (600mg/kgd) of each group, continuous modeling
28d, the physiological saline of blank control group intraperitoneal injection equivalent.Daily free water.
The Collecting and dealing of 2.4 samples：
In after last dose, drug withdrawal fasting 1d's experiment mice weighs, eye socket blood sampling, separates serum.Mouse is craned one place
Extremely, brain tissue is taken out rapidly.Serum, brain tissue freeze to be measured in refrigerator.
Result of the test is represented as mean+SD, and single factor test variance is carried out to test data using SPSS 16.0
Analysis, influence result such as table of the bitter buckwheat bud chewable tablets powder to D- galactolipin induced oxidation damage model mice serum mda contents
Shown in 2.
Influence of the bitter buckwheat bud chewable tablets powder of table 2 to D- galactolipin induced oxidation damage model mice serum MDA contents
Result is expressed as mean+SD, and there is subscript same letter then to represent that there was no significant difference (P ＜ 0.05).
Shown by the results of comparison of table 2：Compared with Normal group, model control group mice serum MDA contents substantially rise
It is high；Compared with model control group, high, the bitter buckwheat bud chewable tablets powder of middle dosage can significantly reduce MDA in exhausted mining areas serum
Content.
Bitter buckwheat bud chewable tablets powder to D- galactolipin induced oxidation damage model mouse brains GSH-PX, T-SOD, MDA activity and
The influence result of content is as shown in table 3.
The bitter buckwheat bud chewable tablets powder of table 3 is to D- galactolipin induced oxidation damage model mouse brains GSH-PX, T-SOD, MDA activity
Influence
Result is expressed as mean+SD, and there is subscript same letter then to represent that there was no significant difference (P ＜ 0.05).
Table 3 shows, compared with Normal group, model control group mouse brain GSH-PX activity is significantly reduced；With model pair
Compared according to group, positive controls and bitter buckwheat bud chewable tablets powder are high, middle dose group GSH-PX activity is notable raises.With Normal group
Compare, model control group mouse brain T-SOD activity is reduced；Compared with model control group, positive controls and bitter buckwheat bud chewable tablets
Powder is low, middle dose group T-SOD activity is raised, and high dose group T-SOD activity is significantly raised.Compared with Normal group, mould
The reduction of type control group mice brain MDA contents；Compared with model control group, positive controls and bitter buckwheat bud chewable tablets powder it is low, middle dose
Amount group MDA contents are reduced, and high dose group MDA contents are significantly reduced.
To sum up result of the test confirms that bitter buckwheat bud chewable tablets of the invention has certain antioxidation, containing it is high, in
The bitter buckwheat bud chewable tablets powder of dosage can significantly reduce the content of MDA in serum；The bitter buckwheat bud chewable tablets powder of high, middle dosage can be notable
Improve brain tissue GSH-PX activity；The bitter buckwheat bud chewable tablets powder of high dose is remarkably improved brain tissue T-SOD activity；High dose
Bitter buckwheat bud chewable tablets powder can significantly reduce the content of MDA in brain tissue.
Above-described embodiment is only intended to clearly illustrate example, and not to the restriction of implementation method.For institute
For the those of ordinary skill in category field, the change or change of other multi-forms can also be made on the basis of the above description
It is dynamic.There is no need and unable to be exhaustive to all of implementation method.And the obvious change or change thus extended out
Among moving still in the protection domain of the invention.
Claims (7)
1. a kind of bitter buckwheat bud chewable tablets with healthcare function, it is characterised in that the bitter buckwheat bud chewable tablets is by following quality percentage
The raw material composition of content：
2. the bitter buckwheat bud chewable tablets with healthcare function according to claim 1, it is characterised in that the bitter buckwheat bud chewable tablets
It is made up of the raw material of following weight/mass percentage composition：
3. the bitter buckwheat bud chewable tablets with healthcare function according to claim 2, it is characterised in that the bitter buckwheat bud chewable tablets
It is made up of the raw material of following weight/mass percentage composition：Bitter buckwheat bud powder 25%, maltodextrin 25.025%, microcrystalline cellulose 25%,
Xylitol 24.6%, stevioside 0.25%, menthol 0.125%.
4. the bitter buckwheat bud chewable tablets with healthcare function according to claim any one of 1-3, it is characterised in that：In raw material
Also include magnesium stearate, the content of magnesium stearate is the 0.6-1.0% of other raw material gross masses.
5. the preparation method of the bitter buckwheat bud chewable tablets with healthcare function described in a kind of claim 1, it is characterised in that including
Following steps：
(1) drying bitter buckwheat bud is crushed, crosses 100 mesh sieves and bitter buckwheat bud powder is obtained, 400-600W is low fiery frying 6-10 minutes, standby；
(2) maltodextrin, microcrystalline cellulose, xylitol, stevioside and menthol are taken to crush, 100 mesh sieves is crossed respectively, will crushed
Bitter buckwheat bud powder, maltodextrin, microcrystalline cellulose, xylitol, stevioside, menthol be mixed and stirred for uniformly according to formula ratio,
Obtain mixed powder；
(3) mixed powder in step (2) is slowly added to 50%-75% ethanol solutions as adhesive, the humidity of material is adjusted,
It is made softwood, softwood should be held agglomerating, touch and dissipate, and softwood is crossed into 20 mesh sieves wet grain is obtained；
(4) wet grain is placed in into the drying box that temperature is 50-100 DEG C to be dried, is dried to its water content below 5%, obtained
Dry particle；
(5) dry particle is weighed, sprays appropriate 50%-75% alcohol, stirred, compressing tablet is obtained with healthcare function
Bitter buckwheat bud chewable tablets.
6. preparation method according to claim 5, it is characterised in that the drying bitter buckwheat bud in the step (1) is by following
Method is obtained：The bitter buckwheat wash seeds for screening full grains are clean, and 12- is soaked for the 2-3 times of clear water of buckwheat seed volume
24h, soaked seed is uniformly sowed seeds in the seedlings nursing plate that tiling has wet gauze, is placed in 20-25 DEG C of temperature, humidity for 75%-
Vernalization 24-48h in 80% dark surrounds, under conditions of identical temperature, humidity and daily illumination 8-12h cultivate,
Timing is sprayed water, and is harvested after 10-12d；Fresh bitter buckwheat bud is uniformly spread out, 60 DEG C of -100 DEG C of heated-air dryings to water content are less than 5%,
Be filled to hermetic bag freezing keep in dark place it is standby.
7. the preparation method according to claim 5 or 6, it is characterised in that the step (5) is that dry particle is weighed, plus
Enter dolomol, be well mixed, spray appropriate 50%-75% alcohol, stir, compressing tablet is obtained with healthcare function
Bitter buckwheat bud chewable tablets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611054875.5A CN106722160A (en) | 2016-11-25 | 2016-11-25 | A kind of bitter buckwheat bud chewable tablets with healthcare function and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611054875.5A CN106722160A (en) | 2016-11-25 | 2016-11-25 | A kind of bitter buckwheat bud chewable tablets with healthcare function and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106722160A true CN106722160A (en) | 2017-05-31 |
Family
ID=58910761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611054875.5A Pending CN106722160A (en) | 2016-11-25 | 2016-11-25 | A kind of bitter buckwheat bud chewable tablets with healthcare function and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106722160A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109588714A (en) * | 2019-02-20 | 2019-04-09 | 吉林大学 | A kind of panax ginseng fruit powder chewable tablet and preparation method thereof with anti-senescence function |
| CN116058496A (en) * | 2022-09-20 | 2023-05-05 | 河北龙河面业有限公司 | Composite tartary buckwheat instant tablet and production method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101411374A (en) * | 2008-12-04 | 2009-04-22 | 李从国 | Bitter-buckwheat embryo tea and preparation method thereof |
| CN102212449A (en) * | 2011-05-26 | 2011-10-12 | 成都大学 | Fagopyrum tataricm gaertn bud health-care wine |
| CN105394546A (en) * | 2015-12-23 | 2016-03-16 | 四川彝家山寨黑苦荞食品有限公司 | Black tartary buckwheat essence buccal tablet and processing method thereof |
| CN105851964A (en) * | 2016-04-28 | 2016-08-17 | 马鞍山菌菌食品科技有限公司 | Burdock-papaya healthcare chewable tablets and preparation method thereof |
-
2016
- 2016-11-25 CN CN201611054875.5A patent/CN106722160A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101411374A (en) * | 2008-12-04 | 2009-04-22 | 李从国 | Bitter-buckwheat embryo tea and preparation method thereof |
| CN102212449A (en) * | 2011-05-26 | 2011-10-12 | 成都大学 | Fagopyrum tataricm gaertn bud health-care wine |
| CN105394546A (en) * | 2015-12-23 | 2016-03-16 | 四川彝家山寨黑苦荞食品有限公司 | Black tartary buckwheat essence buccal tablet and processing method thereof |
| CN105851964A (en) * | 2016-04-28 | 2016-08-17 | 马鞍山菌菌食品科技有限公司 | Burdock-papaya healthcare chewable tablets and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李静舒: "《山西广播电视大学学报》", 31 December 2013 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109588714A (en) * | 2019-02-20 | 2019-04-09 | 吉林大学 | A kind of panax ginseng fruit powder chewable tablet and preparation method thereof with anti-senescence function |
| CN116058496A (en) * | 2022-09-20 | 2023-05-05 | 河北龙河面业有限公司 | Composite tartary buckwheat instant tablet and production method thereof |
| CN116058496B (en) * | 2022-09-20 | 2024-04-05 | 河北龙河面业有限公司 | Composite tartary buckwheat instant tablet and production method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106234926B (en) | Selenium-rich five cereals nutrient instant powder and preparation method thereof | |
| CN102242070B (en) | Method for artificially culturing paecilomyces cicadae and application of culturing product thereof | |
| CN103005431B (en) | Seedless roxburgh rose-angelica keiskei composite chewable tablet and preparation method thereof | |
| CN103141679B (en) | Composite sheep feed containing Chinese medicinal herbs | |
| KR101723206B1 (en) | Pills for health supplement food comprising extracts of protaetia brebitarsis larba and manufacturing method for the same | |
| CN102919836A (en) | Health-care product capable of reducing blood glucose, releasing pressure, reducing lipid, relaxing bowel, beautifying, losing weight and resisting fatigue and production process thereof | |
| CN103099089A (en) | Health-care product for reducing blood sugar and blood pressure, relaxing bowels, losing weight, resisting fatigue and improving sexual function and production technology thereof | |
| CN108041201A (en) | A kind of Fu tea plants powder and preparation method thereof | |
| CN103907817A (en) | Whole grain powder manufacturing method and whole grain powder product | |
| CN106942729A (en) | A kind of nutrient formulation powder for being adapted to gentle constitution and preparation method thereof | |
| CN100444746C (en) | A refined health food of high and cold mountain area crop and processing technology thereof | |
| CN105394546A (en) | Black tartary buckwheat essence buccal tablet and processing method thereof | |
| KR100707733B1 (en) | Drinking water for a diabetic and manufacturing process thereof | |
| CN106722160A (en) | A kind of bitter buckwheat bud chewable tablets with healthcare function and preparation method thereof | |
| CN102488198A (en) | Antioxidant health food preparation for protecting cardiovascular system and its preparation method | |
| CN105795480A (en) | Extraction and analysis method and application of flavone in buckwheat | |
| CN106962563A (en) | A kind of black instant health food tea using sedum aizoon as main component | |
| CN107348350A (en) | A kind of noodles for adjusting blood glucose and preparation method thereof | |
| KR101747793B1 (en) | The manufacturing method of Korean rice cake flavored with Cudrania Tricuspidata | |
| CN102987402B (en) | Plateau natural plant food with balance nutrition and preparation method thereof | |
| CN110150678A (en) | Ginseng dietary fiber chewable tablets and preparation method thereof | |
| CN108552383A (en) | A kind of corn stigma dandelion herb tea and preparation method thereof | |
| CN108902972A (en) | A kind of lithocarpus litseifolius chewable tablets and preparation method thereof | |
| CN107549614A (en) | Three high meals powder and preparation method thereof are nursed one's health in a kind of dietotherapy | |
| CN107041445A (en) | A kind of bamboo juice leaf of bamboo health protection tea for preventing and treating hypertension, hyperglycemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |